Pharmaceutical Industry
NewslettersDigitalization could be the answer to better health care for patients. But first, they need to trust it
By Eamon BarrettJuly 21, 2023
HealthBiden administration pushes Walgreens, CVS and Walmart to tout drug cost benefits of Inflation Reduction Act as drugmakers sue government
By Riley Griffin and BloombergJuly 19, 2023
FinanceThe A.I. mania is so red hot that a small $50 million investment from Nvidia sent an obscure biotech firm’s shares up a record 78%
By Angel Adegbesan and BloombergJuly 12, 2023
HealthOzempic isn’t alone. A whole class of ‘revolutionary’ weight-loss drugs is on the market—but only for the wealthy
By Rachel ShinJuly 9, 2023
By Jane ThierJune 24, 2023
FeaturesThe maker of Ozempic and Wegovy is researching groundbreaking new drugs to stop people from becoming obese in the first place
By Vivienne WaltJune 21, 2023
HealthThe ADHD drug shortage is spreading as supplies of a popular alternative to Adderall run worryingly low
By Ike Swetlitz and BloombergJune 20, 2023
SuccessGen Z needs brand-new skills to climb to the C-suite: ‘What got me here will not get them there,’ says health care CEO
By Jane ThierJune 2, 2023
By Fortune EditorsMay 31, 2023
CommentaryWhy the underestimated economic burden of rare diseases could be costing the U.S. trillions of dollars
By Giacomo ChiesiMay 25, 2023
HealthA Colorado panel of medical and pharmacy experts will decide whose medicine to make affordable this summer
By Markian Hawryluk and KFF Health NewsMay 22, 2023
CommentarySanofi CEO: ‘Europe’s lead in life sciences R&D is eroding–but co-localized hubs could allow it to keep up’
By Paul HudsonMay 17, 2023
By Matthew Perrone and The Associated PressApril 25, 2023
Most Popular
